Summary of Significant Accounting Policies - Disaggregation Of Revenue (Details) - USD ($)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Net Revenue	$ 63,388,617	$ 57,300,281
United States
Net Revenue	54,385,000	50,406,000
Rest of World
Net Revenue	9,004,000	6,894,000
Concentrate Products [Member]
Net Revenue	63,116,000	57,071,000
Concentrate Products [Member] | United States
Net Revenue	54,385,000	50,406,000
Concentrate Products [Member] | Rest of World
Net Revenue	8,731,000	6,665,000
Product License Agreements
Net Revenue	2,400,000	2,300,000
Product License Agreements | Drug Revenue [Member]
Net Revenue	273,000	229,000
Product License Agreements | Drug Revenue [Member] | Rest of World
Net Revenue	273,000	229,000
Product License Agreements | Concentrate Products [Member]
Net Revenue	2,121,000	2,099,000
Product License Agreements | Concentrate Products [Member] | United States
Net Revenue	2,121,000	2,099,000
Product Sales [Member]
Net Revenue	61,000,000	55,000,000
Product Sales [Member] | Concentrate Products [Member]
Net Revenue	60,995,000	54,972,000
Product Sales [Member] | Concentrate Products [Member] | United States
Net Revenue	52,264,000	48,307,000
Product Sales [Member] | Concentrate Products [Member] | Rest of World
Net Revenue	$ 8,731,000	$ 6,665,000